Quantum Biopharma Ltd. (QNTM) stock
Close on Nov 13, 2026Market cap $6.26MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $6.26M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.79
- Dividend yield
- –
- Free cash flow yield
- –
Trading
- Previous close
- $1.78
- Open
- $1.75
- Day's range
- $1.60 – $1.77
- Volume
- 87,534
- Average volume (20 days)
- 94,896
- Beta (5 years)
- 0.93
- 52-week range
- $1.60 – $12.42
- RSI (14 days)
- 21.9
- Volatility (1 year)
- 141.5%
- Relative volume
- 0.50×
- WACC
- 9.7%
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | QNTM | S&P 500 | Difference | QNTM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -44.3% | -3.0% | −41.3 pts | ||
| 3 months | -50.2% | -2.8% | −47.4 pts | ||
| Year to date | -77.9% | +11.5% | −89.4 pts | ||
| 1 year | -79.1% | +13.5% | −92.5 pts | ||
| 3 years | -97.6% | +77.7% | −175.3 pts | -71.2% | +21.1% |
| 5 years | -98.4% | +72.6% | −171.0 pts | -56.3% | +11.5% |
| 10 years | -99.9% | +308.2% | −408.1 pts | -50.0% | +15.1% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
Free cash flow
Press releases
Releases Quantum Biopharma filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Quantum Biopharma
Pharmaceutical Preparations
Quantum BioPharma Ltd. is a biopharmaceutical company engaged in the research and development of drug candidates for neurodegenerative diseases and alcohol misuse, as well as functional beverages. Its core clinical pipeline features Lucid-MS (Lucid-21-302), a product candidate targeted at preventing and reversing myelin degradation in the treatment of multiple sclerosis. The company also advances treatments for alcohol misuse and holds rights to related commercial technologies. Its customer base and commercial target audience include healthcare systems, physicians, patients, healthcare payors, and retail consumers who purchase its functional beverage products through commercial distribution partners.
Company profile, executives and historyQuantum Biopharma stock: common questions
What is Quantum Biopharma's stock price?
QNTM closed at $1.61 on Nov 13, 2026, down 9.55% on the day. Over the past 52 weeks it traded between $1.60 and $12.42.
What is Quantum Biopharma's market cap?
Quantum Biopharma was worth $6.26M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
Does Quantum Biopharma pay a dividend?
No. Quantum Biopharma has not paid a cash dividend over the last twelve months.
How has QNTM stock performed over the past year?
Including dividends, QNTM returned -79.1% over the past year, against +13.5% for the S&P 500.
How many QNTM shares are sold short?
0M shares were sold short at the latest FINRA report, 11.32% of the float, or 4.5 days of average trading volume.
Who are Quantum Biopharma's competitors?
Companies most similar to Quantum Biopharma by business, industry and size include PBM, MSLE, TLSA, BHVN, ALKS.
See a number that looks wrong?